Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Scott

Showing results (291-300 of 360) with videos related to

Pageof 36
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2003
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptorAchim A Jungbluth, Elisabeth Stockert, H J Su Huang, et al.
Nature Neuroscience|April 26, 2016
Control of glioblastoma tumorigenesis by feed-forward cytokine signalingArezu Jahani-Asl, Hang Yin, Vahab D Soleimani, et al.
European Radiology|November 7, 2013
Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinomaJoe H Chang, Daryl Lim Joon, Sze Ting Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancersRebecca A Herbertson, Niall C Tebbutt, Fook-Thean Lee, et al.
The Journal of Biological Chemistry|March 16, 2004
CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptorFrancesca Walker, Suzanne G Orchard, Robert N Jorissen, et al.
BMJ Open|November 18, 2022
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with <sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocolFiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 30, 2025
DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of <sup>177</sup>Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell CarcinomaCameron N Johnstone, Laura D Osellame, Zhipeng Cao, et al.
The Lancet. Oncology|October 19, 2022
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialJames P Buteau, Andrew J Martin, Louise Emmett, et al.
The Lancet. Oncology|March 7, 2021
Medical imaging and nuclear medicine: a Lancet Oncology CommissionHedvig Hricak, May Abdel-Wahab, Rifat Atun, et al.
Leukemia|March 11, 2023
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP studyKate Manos, Geoffrey Chong, Colm Keane, et al.
Pageof 36

Showing results (291-300 of 360) with videos related to

Sort By:
Pageof 36
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2003
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptorAchim A Jungbluth, Elisabeth Stockert, H J Su Huang, et al.
Nature Neuroscience|April 26, 2016
Control of glioblastoma tumorigenesis by feed-forward cytokine signalingArezu Jahani-Asl, Hang Yin, Vahab D Soleimani, et al.
European Radiology|November 7, 2013
Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinomaJoe H Chang, Daryl Lim Joon, Sze Ting Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancersRebecca A Herbertson, Niall C Tebbutt, Fook-Thean Lee, et al.
The Journal of Biological Chemistry|March 16, 2004
CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptorFrancesca Walker, Suzanne G Orchard, Robert N Jorissen, et al.
BMJ Open|November 18, 2022
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with <sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocolFiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 30, 2025
DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of <sup>177</sup>Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell CarcinomaCameron N Johnstone, Laura D Osellame, Zhipeng Cao, et al.
The Lancet. Oncology|October 19, 2022
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialJames P Buteau, Andrew J Martin, Louise Emmett, et al.
The Lancet. Oncology|March 7, 2021
Medical imaging and nuclear medicine: a Lancet Oncology CommissionHedvig Hricak, May Abdel-Wahab, Rifat Atun, et al.
Leukemia|March 11, 2023
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP studyKate Manos, Geoffrey Chong, Colm Keane, et al.
Pageof 36